Biosimilar-to-biosimilar switching: what is the rationale and current experience?
E Mysler, VF Azevedo, S Danese, D Alvarez, N Iikuni… - Drugs, 2021 - Springer
Over time, clinicians have become increasingly comfortable embracing the prescription of
biosimilars—highly similar versions of innovator or reference biological agents—for their …
biosimilars—highly similar versions of innovator or reference biological agents—for their …
Anti-TNF biosimilars in Crohn's disease: a patient-centric interdisciplinary approach
L Peyrin-Biroulet, S Danese, F Cummings… - Expert Review of …, 2019 - Taylor & Francis
Introduction: The purpose of this review is to highlight the role of biosimilars in early
treatment in IBD and introduce ways to facilitate a patient-centric switching process through …
treatment in IBD and introduce ways to facilitate a patient-centric switching process through …